ISSN: 2581 – 3633
PubMed - National Library of Medicine - ID: 101745081

International Journal of Medical Science and Advanced Clinical Research (IJMACR)

Available Online at:www.ijmacr.com

Volume – 7, Issue – 6, November - 2024, Page No. : 06 – 10

Emerging Non-invasive Diagnostic Approaches in Oral Squamous Cell Carcinoma: A Comprehensive Review

[1]Dr. Rohit Chaudhary, Senior Resident, Department of Orthodontics, Maulana Azad Institute of Dental Sciences, New Delhi.

[2]Dr. Seelak Ram Poonia, BDS, Manav Rachna Dental College, Faridabad.

[3]Dr. Kiran Shankaraiah Palakurthy, PhD Student, Prosthodontics, Faculty of Dentistry. University of western Cape. Capetown. South Africa.

[4]Dr. Vaibhav Jagannathrao Salunke, MDS Oral Medicine and Radiology, Dentist, (NOHP) Latur, Deshmukh Dental Clinic Latur.

[5]Dr. Keerat Preet Kour, Senior Resident. Dr. Baba Sahib Ambedkar Hospital, Delhi

[6]Dr. R Sumukh Bharadwaj, Post Graduate Student, Department of Conservative Dentistry and Endodontics, JSS Dental College and Hospital, JSS AHER, Mysuru.

Corresponding Author: Dr. Rohit Chaudhary, Senior Resident, Department of Orthodontics, Maulana Azad Institute of Dental Sciences, New Delhi.

How to citation this article: Dr. Rohit Chaudhary, Dr. Seelak Ram Poonia, Dr. Kiran Shankaraiah Palakurthy, Dr. Vaibhav Jagannathrao Salunke, Dr. Keerat Preet Kour, Dr. R Sumukh Bharadwaj, "Emerging Non-invasive Diagnostic Approaches in Oral Squamous Cell Carcinoma: A Comprehensive Review", IJMACR- November - 2024, Volume – 7, Issue - 6, P. No. 06 – 10.

Type of Publication: Review Article

Conflicts of Interest: Nil

Abstract

Oral squamous cell carcinoma (OSCC) is a prevalent and life-threatening malignancy, often diagnosed at advanced stages due to the invasiveness and delay associated with traditional biopsy-based diagnostics. The emergence of non-invasive diagnostic approaches holds promise for early detection, improved patient compliance, and better prognosis. This review explores recent advancements in non-invasive OSCC diagnostics, including salivary biomarkers, liquid biopsy, optical imaging, and artificial intelligence (AI)-enhanced tools. Each method's diagnostic accuracy, limitations, and clinical potential are analyzed, highlighting how these innovations can complement or eventually replace conventional diagnostic methods. While challenges in standardization and validation remain, the integration of these non-invasive technologies into clinical practice could significantly impact the early diagnosis and management of OSCC.

Keywords: Oral squamous cell carcinoma, OSCC, non-invasive diagnostics, salivary biomarkers, liquid biopsy, optical imaging, artificial intelligence, early detection, head and neck cancer.

Introduction

Oral squamous cell carcinoma (OSCC) is a malignancy originating from the squamous cells lining the oral cavity and oropharynx, constituting over 90% of oral cancers. Early detection is crucial for improving survival rates, yet many cases are diagnosed at advanced stages due to asymptomatic progression and a lack of accessible early detection methods. Traditional diagnosis, relying heavily on clinical examination and biopsy, has limitations due to invasiveness, patient discomfort, and diagnostic delay. Non-invasive diagnostic approaches have gained considerable attention as potential alternatives, offering reduced risk, faster results, and better patient compliance.[1-3]

This review aims to present a comprehensive overview of non-invasive diagnostic approaches for OSCC, including imaging techniques, molecular markers, salivary diagnostics, and artificial intelligence (AI)-enhanced tools. By examining recent advancements, we aim to outline each method's diagnostic utility, limitations, and future potential.

Non-invasive Diagnostic Approaches in OSCC

1. Salivary Diagnostics [4-7]

Saliva is an accessible and reliable medium containing various biomolecules, making it an ideal candidate for OSCC diagnostics. Advances in salivary diagnostics focus on detecting specific biomarkers, such as DNA, RNA, proteins, and metabolites associated with OSCC.

MicroRNAs (miRNAs): Specific miRNAs like miR-21, miR-31, and miR-184 have been consistently overexpressed in OSCC patients, suggesting their potential as diagnostic biomarkers.

Proteomic Analysis: Proteins like interleukins (IL-6, IL-8), matrix metalloproteinases (MMPs), and various growth factors in saliva show differential expression in OSCC patients. Multiplex assays are now available, enabling simultaneous detection of multiple protein markers.

DNA Methylation: Aberrant DNA methylation patterns, especially in tumour-suppressor genes, can be detected in salivary DNA. Studies have identified methylated promoters like p16 and MGMT as potential markers for OSCC.

Salivary diagnostics offer the advantage of being painless, simple, and easy to collect. However, standardization and reproducibility of biomarker tests remain challenges that need further exploration.

Liquid Biopsy [8-10]

Liquid biopsy involves detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) in blood samples. It is gaining momentum as a noninvasive tool in cancer diagnostics, including OSCC.

Circulating Tumor DNA (ctDNA): ctDNA analysis helps in detecting genetic mutations and methylation patterns characteristic of OSCC. Mutations in genes like TP53, PIK3CA, and EGFR have been linked to OSCC progression and are detectable through ctDNA.

Circulating Tumor Cells (CTCs): Although less prevalent in OSCC than in other cancers, CTCs offer diagnostic information and can be tracked over time to monitor disease progression.

Extracellular Vesicles (EVs): These are small vesicles containing nucleic acids and proteins derived from

tumor cells. The EVs' RNA and protein profiles can be assessed for OSCC-specific markers.

While liquid biopsies are highly promising, their accuracy can be affected by the low abundance of OSCC-related biomarkers in blood samples, necessitating further refinement for routine clinical application.

Optical Imaging Techniques [11-13]

Advanced optical imaging techniques, including autofluorescence, narrow-band imaging (NBI), and optical coherence tomography (OCT), have shown potential for noninvasive OSCC diagnosis.

Autofluorescence Imaging: This technique utilizes endogenous tissue fluorescence to detect OSCC-associated changes in tissue. Normal and abnormal tissues emit different fluorescence patterns when excited by specific light wavelengths, aiding early OSCC identification.

Narrow-Band Imaging (NBI): NBI enhances mucosal visualization by using narrow-band light filters, providing clearer images of microvascular structures and epithelial changes associated with OSCC. This method is particularly useful for identifying potentially malignant lesions.

Optical Coherence Tomography (OCT): OCT provides high-resolution cross-sectional imaging of oral tissues, allowing for detailed assessment of tissue architecture. It has proven helpful in differentiating between malignant and benign oral lesions.

Optical imaging techniques offer rapid, non-invasive visualization of potentially malignant tissues, yet are often used as adjuncts rather than standalone diagnostic tools due to their limited ability to confirm malignancy at a molecular level.

Artificial Intelligence and Machine Learning in Imaging and Biomarker Analysis [14-17]

The integration of artificial intelligence (AI) and machine learning (ML) with imaging and biomarker data has opened new possibilities in OSCC diagnostics. AI algorithms can enhance image analysis, increasing the accuracy of techniques like autofluorescence and NBI.

Deep Learning for Image Analysis: Convolutional neural networks (CNNs) have demonstrated high accuracy in analyzing imaging data, aiding early diagnosis of OSCC from standard clinical images and advanced optical scans.

Pattern Recognition in Biomarker Data: AI algorithms have been applied to analyze complex datasets from salivary diagnostics and liquid biopsies, identifying patterns that could distinguish OSCC from benign conditions more accurately.

AI-enhanced diagnostic tools hold promise for rapid, reliable OSCC detection. However, the successful integration of these methods into clinical practice requires extensive validation to minimize false positives and optimize accuracy.

Challenges and Future Directions [18-22]

While emerging non-invasive approaches offer promise, several challenges persist:

Standardization: There is a lack of standardized protocols for sample collection, processing, and analysis across various non-invasive diagnostic methods, which affects reproducibility.

Sensitivity and Specificity: Non-invasive approaches must attain high sensitivity and specificity to replace or complement traditional biopsy methods effectively.

Integration into Clinical Practice: For these approaches to be widely adopted, they must be validated

in large-scale clinical trials and integrated into existing diagnostic workflows seamlessly.

Future research should focus on addressing these challenges and improving the diagnostic capabilities of non-invasive tools. Additionally, developing cost-effective and user-friendly devices will be essential for their widespread adoption, especially in low-resource settings.

Conclusion

Emerging non-invasive diagnostic approaches in OSCC hold significant promise for transforming early detection and management. Salivary diagnostics, liquid biopsies, optical imaging techniques, and AI-based diagnostic tools offer less invasive and potentially more accessible options than traditional biopsy methods. While these technologies are not yet fully integrated into routine clinical practice, ongoing research and validation efforts may soon position them as essential components in the diagnostic landscape for OSCC. These advancements could lead to earlier detection, improved prognosis, and a better quality of life for OSCC patients worldwide.

This comprehensive review underscores the potential of non-invasive diagnostic methods in OSCC, suggesting that a multimodal approach that combines these emerging technologies with traditional diagnostic practices may ultimately yield the best clinical outcomes.

References

1. Ng, J. H., Iyer, N. G., Tan, M.-H. & Edgren, G. Changing epidemiology of oral squamous cell carcinoma of the tongue: a global study. Head Neck 39, 297–304 (2017).
2. Linsen, S. S., Gellrich, N.-C. & Krüskemper, G. Age-and localization-dependent functional and psychosocial impairments and health related quality of life six months after OSCC therapy. Oral Oncol. 81, 61–68 (2018).
3. Maymone, M. B. C. et al. Premalignant and malignant oral mucosal lesions: Clinical and pathological findings. J. Am. Acad. Dermatol. 81, 59–71 (2019).
4. Brandizzi, D., Gandolfo, M., Velazco, M. L., Cabrini, R. L. & Lanfranchi, H. Clinical features and evolution of oral cancer: a study of 274 cases in Buenos Aires, Argentina. Med. Oral Patol. Oral Cir. Bucal. 13, E544-8 (2008).
5. Odell, E., Kujan, O., Warnakulasuriya, S. & Sloan, P. Oral epithelial dysplasia: recognition, grading and clinical significance. Oral Dis. 27, 1947–1976 (2021).
6. Bagan, J., Sarrion, G. & Jimenez, Y. Oral cancer: clinical features. Oral Oncol. 46, 414–417 (2010).
7. Scully, C. & Bagan, J. V. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis. 15, 388–399 (2009).
8. Omura, K. Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma. Int. J. Clin. Oncol. 19, 423–430 (2014).
9. Warnakulasuriya, S. Oral potentially malignant disorders: A comprehensive review on clinical aspects and management. Oral Oncol. 102, 104550 (2020).
10. Yap, T. et al. Non-invasive screening of a microRNA-based dysregulation signature in oral cancer and oral potentially malignant disorders. Oral Oncol. 96, 113–120 (2019).
11. Warnakulasuriya, S. Clinical features and presentation of oral potentially malignant

disorders. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 125, 582–590 (2018).

12. Tarakji, B. Dentists' perception of oral potentially malignant disorders. Int. Dent. J. 72, 414–419 (2022).
13. Kerr, A. R. & Lodi, G. Management of oral potentially malignant disorders. Oral Dis. 27, 2008–2025 (2021).
14. Mello, F. W. et al. Prevalence of oral potentially malignant disorders: a systematic review and meta-analysis. J. Oral Pathol. Med. 47, 633–640 (2018).
15. Warnakulasuriya, S., Johnson, N. W. & van der Waal, I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J. Oral Pathol. Med. 36, 575–580 (2007).
16. Villa, A. & Sonis, S. Oral leukoplakia remains a challenging condition. Oral Dis. 24, 179–183 (2018).
17. Holmstrup, P. & Dabelsteen, E. Oral leukoplakia—to treat or not to treat. Oral Dis. 22, 494–497 (2016).
18. Carrard, V. C. & van der Waal, I. A clinical diagnosis of oral leukoplakia; A guide for dentists. Med. Oral Patol. Oral Cir. Bucal 23, e59 (2018).
19. Warnakulasuriya, S. et al. Oral potentially malignant disorders: a consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 27, 1862–1880 (2021).
20. Pentenero, M., Meleti, M., Vescovi, P. & Gandolfo, S. Oral proliferative verrucous leucoplakia: are there particular features for such an ambiguous entity? A systematic review. Br. J. Dermatol. 170, 1039–1047 (2014).
21. Yang, S.-W. et al. Clinical characteristics of narrow-band imaging of oral erythroplakia and its correlation with pathology. BMC Cancer 15, 1–8 (2015).
22. Holmstrup, P. Oral erythroplakia—what is it? Oral Dis. 24, 138–143 (2018).